TriSalus Life Sciences Inc. announced that Jodi Devlin has joined the company as President of TriSalus Therapeutics. In this newly established role, Ms. Devlin will be responsible for developing and executing the go-to-market strategy for TriSalus? SD-101 therapeutic candidate, building the Company?s therapeutic marketing operations, working with the clinical team to incorporate commercial and payor needs into the clinical strategy, developing and executing the Company?s patient access and payor engagement strategy and developing a distinctive patient experience for the SD-101 treatment.

Ms. Devlin bring over 34 years of experience in biopharmaceuticals to TriSalus. Most recently, she served as Chief Executive Officer of AltaThera Pharmaceuticals, where she built the company?s vision and strategy, executed its turnaround, and oversaw the FDA approval of its product. Prior to serving as CEO, she held the role of Chief Commercial Officer at AltaThera, overseeing sales, marketing, pricing, reimbursement, and health economics.

Prior to that, Ms. Devlin served as the Vice President and General Manager of the Hospital Acute Care business at Mallinckrodt Pharmaceuticals, where she led the strategy and commercialization of Ofirmev. Ms. Devlin has also served as a Senior Executive at Baxter/Baxalta, and Abbott AbbVie, where she led the commercialization, launch and clinical strategy for over 20 products, including the company?s product HUMIRA. She currently serves on the Board of Directors of Fitabeo Therapeutics.

Ms. Devlin holds a Bachelor of Science in Nursing degree from Oklahoma University and a Master of Business Administration from Washington University?s Olin School of Business.